- Lois et règlements
- eservices
-
Media Center
Hotline for Health Services for Displaced Lebanese 1787Hotline for the Patient Admission to Hospitals 01/832700COVID-19 Vaccine Registration Form covax.moph.gov.lbMoPH Hotline 1214
Are you a new member? Sign up now
close
KESIMPTA - 20mg/0.4ml - 1
| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L04AA52 | BioTech | Ofatumumab - 20mg/0.4ml | 10677 | 153320/1 | KESIMPTA | 20mg/0.4ml | 1 | Injectable solution | SC | Khalil Fattal & Fils S.A.L. | Novartis Pharma Stein AG | Switzerland | 96,542,598 L.L | 2.44 | E2 | Novartis Pharma AG | Switzerland | 2/5/2024 | 0 |